Table 1.
Socio-demographic and clinical characteristics ( n = 734)
| Variable | |
|---|---|
| Female gender |
473 (64%) |
| APOE ϵ4 carrier, (n = 718) |
493 (69%) |
| Solitary living at baseline |
267 (36%) |
| Anti-hypertensives/Cardiac therapy |
290 (40%) |
| Anti-diabetics |
38 (5%) |
| Lipid-lowering agents |
94 (13%) |
| Estrogens |
52 (7%) |
| NSAIDs/Acetylsalicylic acid |
221 (30%) |
| Anti-depressants |
183 (25%) |
| Anti-psychotics |
26 (4%) |
| Anxiolytics/Sedatives/Hypnotics |
111 (15%) |
| Variable |
Mean ± standard deviation |
| Estimated age at onset (years) |
72.3 ± 7.1 |
| Estimated duration of AD at baseline (years) |
2.9 ± 2.0 |
| Age at first assessment (years) |
75.2 ± 6.8 |
| Education (years) |
9.6 ± 2.6 |
| MMSE score at baseline |
23.4 ± 2.0 |
| ADAS-cog score (0–70) at baseline |
17.5 ± 6.7 |
| IADL score at baseline |
14.7 ± 5.0 |
| Number of concomitant medications at baseline | 2.9 ± 2.4 |
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NSAIDs, non-steroidal anti-inflammatory drugs.